Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Free Report) have received a consensus rating of “Moderate Buy” from the nineteen research firms that are currently covering the firm, reports. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $232.32.

ALNY has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, December 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, January 18th. Wells Fargo & Company initiated coverage on Alnylam Pharmaceuticals in a report on Friday, December 8th. They issued an “equal weight” rating and a $171.00 price objective for the company. BMO Capital Markets decreased their price objective on Alnylam Pharmaceuticals from $250.00 to $234.00 and set an “outperform” rating for the company in a research report on Tuesday, October 10th. Finally, Oppenheimer cut shares of Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 11th.

Get Our Latest Stock Report on ALNY

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total value of $5,850,000.00. Following the transaction, the director now owns 16,029 shares of the company’s stock, valued at $3,125,655. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Capital Advisors Ltd. LLC lifted its holdings in Alnylam Pharmaceuticals by 1,480.0% in the second quarter. Capital Advisors Ltd. LLC now owns 158 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 148 shares during the period. Quent Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. KB Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $35,000. Financial Gravity Asset Management Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter valued at about $132,000. Finally, Anchor Investment Management LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $38,000. Institutional investors own 93.98% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $183.93 on Friday. The firm has a 50-day simple moving average of $181.60 and a two-hundred day simple moving average of $181.80. The stock has a market cap of $23.08 billion, a PE ratio of -44.43 and a beta of 0.47. Alnylam Pharmaceuticals has a 1-year low of $148.10 and a 1-year high of $234.70.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $2.76. The firm had revenue of $750.53 million for the quarter, compared to analyst estimates of $406.14 million. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

(Get Free Report

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Articles

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with's FREE daily email newsletter.